Concepts (138)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 14 | 2022 | 56 | 1.700 |
Why?
|
| Glioblastoma | 10 | 2023 | 265 | 1.380 |
Why?
|
| Fracture Healing | 5 | 2014 | 35 | 1.190 |
Why?
|
| Ethanol | 6 | 2012 | 250 | 0.940 |
Why?
|
| Tibial Fractures | 4 | 2014 | 36 | 0.790 |
Why?
|
| beta Catenin | 2 | 2014 | 266 | 0.770 |
Why?
|
| Brain Neoplasms | 6 | 2023 | 780 | 0.670 |
Why?
|
| Bony Callus | 2 | 2014 | 5 | 0.540 |
Why?
|
| Wnt Signaling Pathway | 2 | 2014 | 97 | 0.540 |
Why?
|
| Growth Plate | 1 | 2014 | 11 | 0.490 |
Why?
|
| Aggrecans | 1 | 2014 | 43 | 0.490 |
Why?
|
| Chondrocytes | 1 | 2014 | 64 | 0.480 |
Why?
|
| Lithium Chloride | 1 | 2014 | 2 | 0.480 |
Why?
|
| Binge Drinking | 1 | 2014 | 13 | 0.470 |
Why?
|
| Extremities | 1 | 2014 | 168 | 0.450 |
Why?
|
| Kynurenine | 5 | 2022 | 21 | 0.400 |
Why?
|
| Tryptophan | 7 | 2022 | 92 | 0.370 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2014 | 661 | 0.360 |
Why?
|
| Glioma | 2 | 2022 | 292 | 0.340 |
Why?
|
| Cell Differentiation | 1 | 2014 | 1521 | 0.310 |
Why?
|
| Animals | 25 | 2023 | 27272 | 0.300 |
Why?
|
| Bone Density | 1 | 2008 | 209 | 0.300 |
Why?
|
| Osteoporosis | 1 | 2008 | 122 | 0.290 |
Why?
|
| Mice | 13 | 2023 | 11722 | 0.290 |
Why?
|
| Brain | 3 | 2020 | 2269 | 0.240 |
Why?
|
| Immunotherapy | 4 | 2018 | 664 | 0.230 |
Why?
|
| Oncolytic Viruses | 1 | 2022 | 24 | 0.210 |
Why?
|
| Femoral Fractures | 2 | 2011 | 27 | 0.190 |
Why?
|
| Alcoholic Intoxication | 2 | 2011 | 32 | 0.180 |
Why?
|
| Alcoholism | 3 | 2011 | 178 | 0.180 |
Why?
|
| Tryptophan Oxygenase | 2 | 2019 | 9 | 0.180 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2020 | 54 | 0.170 |
Why?
|
| Mice, Transgenic | 2 | 2014 | 1573 | 0.170 |
Why?
|
| Enzyme Assays | 1 | 2019 | 16 | 0.170 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2017 | 129 | 0.170 |
Why?
|
| Rats, Sprague-Dawley | 6 | 2013 | 1236 | 0.160 |
Why?
|
| Lumbar Vertebrae | 2 | 2009 | 151 | 0.150 |
Why?
|
| Immune Tolerance | 1 | 2020 | 337 | 0.150 |
Why?
|
| Radiation, Ionizing | 1 | 2018 | 121 | 0.150 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2018 | 169 | 0.140 |
Why?
|
| Disease Models, Animal | 6 | 2020 | 2347 | 0.140 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 195 | 0.130 |
Why?
|
| Rats | 6 | 2013 | 4039 | 0.130 |
Why?
|
| SOX9 Transcription Factor | 1 | 2014 | 26 | 0.120 |
Why?
|
| Enzyme Inhibitors | 1 | 2018 | 645 | 0.120 |
Why?
|
| Male | 13 | 2020 | 42135 | 0.120 |
Why?
|
| Blotting, Southern | 1 | 2014 | 129 | 0.120 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2014 | 122 | 0.120 |
Why?
|
| Chickens | 1 | 2014 | 212 | 0.120 |
Why?
|
| Neoplasms | 3 | 2020 | 3020 | 0.120 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2014 | 44 | 0.120 |
Why?
|
| In Situ Hybridization | 1 | 2014 | 313 | 0.120 |
Why?
|
| Hedgehog Proteins | 1 | 2014 | 100 | 0.120 |
Why?
|
| Signal Transduction | 2 | 2015 | 3370 | 0.120 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2014 | 69 | 0.110 |
Why?
|
| Aging | 2 | 2016 | 713 | 0.110 |
Why?
|
| DNA Primers | 1 | 2014 | 543 | 0.110 |
Why?
|
| Ketorolac | 1 | 2013 | 6 | 0.110 |
Why?
|
| Fractures, Malunited | 1 | 2012 | 4 | 0.110 |
Why?
|
| Prognosis | 2 | 2017 | 3757 | 0.100 |
Why?
|
| Bone Remodeling | 2 | 2009 | 24 | 0.100 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2012 | 61 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 3 | 2016 | 3202 | 0.100 |
Why?
|
| Biomechanical Phenomena | 2 | 2013 | 472 | 0.100 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 242 | 0.090 |
Why?
|
| Alcohol Drinking | 2 | 2010 | 273 | 0.090 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 1796 | 0.090 |
Why?
|
| Antioxidants | 1 | 2011 | 224 | 0.090 |
Why?
|
| Spine | 1 | 2010 | 102 | 0.090 |
Why?
|
| Biomarkers | 2 | 2018 | 1753 | 0.080 |
Why?
|
| Alcohols | 1 | 2009 | 15 | 0.080 |
Why?
|
| Mice, Knockout | 3 | 2020 | 1990 | 0.080 |
Why?
|
| Bone Resorption | 1 | 2009 | 42 | 0.080 |
Why?
|
| Humans | 15 | 2023 | 88852 | 0.080 |
Why?
|
| Cell Proliferation | 1 | 2014 | 1649 | 0.080 |
Why?
|
| Wound Healing | 1 | 2010 | 359 | 0.080 |
Why?
|
| Gene Expression | 2 | 2010 | 1309 | 0.080 |
Why?
|
| Weight Gain | 1 | 2008 | 119 | 0.080 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 1532 | 0.070 |
Why?
|
| Cytokines | 1 | 2011 | 801 | 0.070 |
Why?
|
| Cell Line, Tumor | 3 | 2018 | 2549 | 0.070 |
Why?
|
| Tumor Microenvironment | 2 | 2022 | 458 | 0.070 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2018 | 470 | 0.070 |
Why?
|
| Gene Expression Profiling | 1 | 2010 | 1428 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2018 | 1533 | 0.060 |
Why?
|
| Aged | 4 | 2023 | 19019 | 0.050 |
Why?
|
| CTLA-4 Antigen | 1 | 2020 | 138 | 0.040 |
Why?
|
| Synapses | 1 | 2022 | 274 | 0.040 |
Why?
|
| Cellular Senescence | 1 | 2020 | 103 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2023 | 657 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2022 | 592 | 0.040 |
Why?
|
| B7-H1 Antigen | 1 | 2020 | 272 | 0.040 |
Why?
|
| HeLa Cells | 1 | 2019 | 511 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 6758 | 0.040 |
Why?
|
| Immune Evasion | 1 | 2018 | 34 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2018 | 305 | 0.040 |
Why?
|
| Coculture Techniques | 1 | 2017 | 172 | 0.040 |
Why?
|
| Enzyme Activation | 1 | 2018 | 698 | 0.030 |
Why?
|
| Treatment Outcome | 3 | 2015 | 8178 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2018 | 276 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 1862 | 0.030 |
Why?
|
| Catalysis | 1 | 2015 | 205 | 0.030 |
Why?
|
| Immunity | 1 | 2015 | 141 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 1213 | 0.030 |
Why?
|
| Middle Aged | 3 | 2020 | 25787 | 0.030 |
Why?
|
| Adult | 3 | 2020 | 26439 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 1708 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 1107 | 0.030 |
Why?
|
| Injections, Intraperitoneal | 1 | 2013 | 101 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 285 | 0.030 |
Why?
|
| Compressive Strength | 1 | 2012 | 24 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 1989 | 0.030 |
Why?
|
| Tensile Strength | 1 | 2012 | 80 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 1146 | 0.030 |
Why?
|
| Mutation | 1 | 2023 | 4121 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 1265 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2018 | 1222 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2017 | 2011 | 0.020 |
Why?
|
| Immunoassay | 1 | 2011 | 91 | 0.020 |
Why?
|
| Temperance | 1 | 2010 | 6 | 0.020 |
Why?
|
| Random Allocation | 1 | 2011 | 328 | 0.020 |
Why?
|
| Alcohol Dehydrogenase | 1 | 2010 | 42 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2013 | 865 | 0.020 |
Why?
|
| Female | 3 | 2020 | 45899 | 0.020 |
Why?
|
| Osteocalcin | 1 | 2009 | 26 | 0.020 |
Why?
|
| RANK Ligand | 1 | 2009 | 10 | 0.020 |
Why?
|
| Osteoprotegerin | 1 | 2009 | 10 | 0.020 |
Why?
|
| Alkaline Phosphatase | 1 | 2009 | 132 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2011 | 901 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2009 | 260 | 0.020 |
Why?
|
| Bone and Bones | 1 | 2009 | 269 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 1938 | 0.020 |
Why?
|
| Acute Disease | 1 | 2009 | 837 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2009 | 465 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2009 | 947 | 0.020 |
Why?
|
| Inflammation | 1 | 2011 | 969 | 0.020 |
Why?
|
| Lung | 1 | 2011 | 1257 | 0.010 |
Why?
|
| Time Factors | 1 | 2013 | 5313 | 0.010 |
Why?
|